| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 36 | 2020 | 103 | 5.120 |
Why?
|
| Substance-Related Disorders | 10 | 2017 | 25 | 2.140 |
Why?
|
| HIV Seropositivity | 15 | 2019 | 20 | 1.860 |
Why?
|
| Neuropsychological Tests | 38 | 2019 | 238 | 1.680 |
Why?
|
| Adult | 56 | 2019 | 794 | 1.480 |
Why?
|
| Middle Aged | 48 | 2020 | 792 | 1.460 |
Why?
|
| AIDS Dementia Complex | 13 | 2018 | 22 | 1.450 |
Why?
|
| Male | 59 | 2020 | 1860 | 1.380 |
Why?
|
| Humans | 73 | 2020 | 2957 | 1.360 |
Why?
|
| Cognition Disorders | 9 | 2018 | 175 | 1.140 |
Why?
|
| Cognition | 13 | 2019 | 220 | 1.130 |
Why?
|
| Cognitive Dysfunction | 7 | 2020 | 165 | 1.130 |
Why?
|
| Female | 38 | 2019 | 1724 | 0.990 |
Why?
|
| HIV-1 | 14 | 2017 | 59 | 0.970 |
Why?
|
| Psychomotor Performance | 12 | 2018 | 34 | 0.920 |
Why?
|
| Acquired Immunodeficiency Syndrome | 7 | 2017 | 8 | 0.910 |
Why?
|
| Decision Making | 3 | 2016 | 19 | 0.860 |
Why?
|
| Sex Characteristics | 2 | 2016 | 14 | 0.790 |
Why?
|
| Hepatitis C | 2 | 2015 | 4 | 0.750 |
Why?
|
| Reaction Time | 11 | 2017 | 29 | 0.670 |
Why?
|
| Cocaine-Related Disorders | 2 | 2017 | 5 | 0.620 |
Why?
|
| Brain | 9 | 2020 | 202 | 0.540 |
Why?
|
| Spatial Learning | 1 | 2017 | 1 | 0.530 |
Why?
|
| Spatial Navigation | 1 | 2017 | 3 | 0.530 |
Why?
|
| Mumps | 1 | 2017 | 1 | 0.520 |
Why?
|
| Mumps Vaccine | 1 | 2017 | 1 | 0.520 |
Why?
|
| Immunization Programs | 1 | 2017 | 1 | 0.520 |
Why?
|
| Epidemiological Monitoring | 1 | 2017 | 7 | 0.520 |
Why?
|
| Anti-HIV Agents | 6 | 2019 | 14 | 0.520 |
Why?
|
| Memory, Episodic | 1 | 2017 | 22 | 0.520 |
Why?
|
| Hospitalization | 1 | 2017 | 49 | 0.510 |
Why?
|
| Risk-Taking | 1 | 2016 | 4 | 0.470 |
Why?
|
| Delay Discounting | 1 | 2015 | 2 | 0.450 |
Why?
|
| Memory | 5 | 2017 | 48 | 0.450 |
Why?
|
| Cohort Studies | 15 | 2020 | 233 | 0.420 |
Why?
|
| Gambling | 2 | 2010 | 2 | 0.400 |
Why?
|
| Aged | 14 | 2019 | 956 | 0.360 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 97 | 0.360 |
Why?
|
| Motor Skills | 1 | 2010 | 3 | 0.320 |
Why?
|
| Affective Symptoms | 1 | 2010 | 1 | 0.320 |
Why?
|
| Unsafe Sex | 1 | 2010 | 1 | 0.320 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2015 | 13 | 0.320 |
Why?
|
| Depression | 5 | 2019 | 59 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2020 | 77 | 0.310 |
Why?
|
| Learning | 1 | 2009 | 20 | 0.300 |
Why?
|
| Adolescent | 6 | 2017 | 247 | 0.300 |
Why?
|
| Age Factors | 6 | 2017 | 89 | 0.300 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 1 | 0.300 |
Why?
|
| Attention | 5 | 2019 | 14 | 0.280 |
Why?
|
| Neuropsychology | 1 | 2008 | 1 | 0.280 |
Why?
|
| Women | 1 | 2008 | 1 | 0.280 |
Why?
|
| Professional Role | 1 | 2008 | 2 | 0.280 |
Why?
|
| Career Choice | 1 | 2008 | 4 | 0.280 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 7 | 0.280 |
Why?
|
| Diabetes Complications | 2 | 2018 | 10 | 0.280 |
Why?
|
| Verbal Learning | 4 | 2015 | 8 | 0.280 |
Why?
|
| HIV Seronegativity | 4 | 2016 | 8 | 0.280 |
Why?
|
| Marijuana Smoking | 2 | 2019 | 2 | 0.270 |
Why?
|
| Sex Factors | 4 | 2019 | 72 | 0.260 |
Why?
|
| Memory, Short-Term | 6 | 2019 | 23 | 0.260 |
Why?
|
| Depressive Disorder | 3 | 2014 | 22 | 0.250 |
Why?
|
| Executive Function | 5 | 2017 | 15 | 0.230 |
Why?
|
| Schizophrenic Psychology | 3 | 2002 | 5 | 0.230 |
Why?
|
| Memory Disorders | 3 | 2017 | 33 | 0.220 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 567 | 0.210 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2015 | 18 | 0.190 |
Why?
|
| Young Adult | 4 | 2017 | 187 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 50 | 0.180 |
Why?
|
| Heroin Dependence | 2 | 2013 | 3 | 0.180 |
Why?
|
| Prefrontal Cortex | 3 | 2014 | 34 | 0.170 |
Why?
|
| Bipolar Disorder | 2 | 2002 | 5 | 0.170 |
Why?
|
| Auditory Perception | 1 | 2001 | 1 | 0.170 |
Why?
|
| Cues | 2 | 2000 | 7 | 0.170 |
Why?
|
| Risk Factors | 7 | 2018 | 275 | 0.160 |
Why?
|
| Self Report | 2 | 2018 | 20 | 0.160 |
Why?
|
| Longitudinal Studies | 6 | 2018 | 260 | 0.160 |
Why?
|
| Disease Progression | 3 | 2015 | 99 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 3 | 2017 | 19 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2019 | 62 | 0.160 |
Why?
|
| Incidence | 2 | 2018 | 110 | 0.160 |
Why?
|
| Neurocognitive Disorders | 2 | 2017 | 9 | 0.160 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 22 | 0.160 |
Why?
|
| Thinking | 1 | 2000 | 2 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2018 | 203 | 0.150 |
Why?
|
| Benzoxazines | 1 | 2019 | 1 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2019 | 2 | 0.150 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 1 | 0.150 |
Why?
|
| Obesity | 2 | 2019 | 38 | 0.140 |
Why?
|
| United States | 6 | 2018 | 243 | 0.140 |
Why?
|
| Individuality | 1 | 2018 | 3 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2018 | 6 | 0.140 |
Why?
|
| White Matter | 1 | 2018 | 8 | 0.140 |
Why?
|
| Comorbidity | 2 | 2015 | 49 | 0.140 |
Why?
|
| Vaccination Coverage | 1 | 2017 | 1 | 0.130 |
Why?
|
| Vaccination | 1 | 2017 | 1 | 0.130 |
Why?
|
| Spain | 1 | 2017 | 2 | 0.130 |
Why?
|
| Alzheimer Disease | 4 | 1992 | 250 | 0.130 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 9 | 0.130 |
Why?
|
| Hippocampus | 1 | 2017 | 41 | 0.130 |
Why?
|
| Marijuana Use | 1 | 2017 | 2 | 0.130 |
Why?
|
| Sexual and Gender Minorities | 1 | 2017 | 3 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 1 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 11 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2017 | 119 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 24 | 0.130 |
Why?
|
| Infant | 1 | 2017 | 122 | 0.130 |
Why?
|
| Smoking | 1 | 2017 | 28 | 0.120 |
Why?
|
| Child | 1 | 2017 | 197 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2010 | 30 | 0.120 |
Why?
|
| Prevalence | 4 | 2017 | 39 | 0.120 |
Why?
|
| Personality Inventory | 1 | 2016 | 7 | 0.120 |
Why?
|
| Mental Recall | 1 | 1995 | 14 | 0.120 |
Why?
|
| Aging | 1 | 2017 | 204 | 0.110 |
Why?
|
| Drug Users | 1 | 2015 | 1 | 0.110 |
Why?
|
| Adiponectin | 1 | 2015 | 1 | 0.110 |
Why?
|
| RNA, Viral | 1 | 2015 | 7 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2015 | 21 | 0.110 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2014 | 1 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2015 | 24 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 46 | 0.110 |
Why?
|
| Menopause | 1 | 2014 | 6 | 0.110 |
Why?
|
| Patient Selection | 1 | 2014 | 11 | 0.100 |
Why?
|
| Apolipoprotein E4 | 1 | 2014 | 76 | 0.100 |
Why?
|
| Anxiety | 2 | 2010 | 18 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2008 | 34 | 0.100 |
Why?
|
| Dementia | 1 | 2014 | 73 | 0.100 |
Why?
|
| Zidovudine | 3 | 1999 | 4 | 0.100 |
Why?
|
| Stroke | 1 | 2013 | 49 | 0.100 |
Why?
|
| Socioeconomic Factors | 2 | 2010 | 27 | 0.100 |
Why?
|
| Psychometrics | 2 | 1995 | 27 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 105 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 14 | 0.090 |
Why?
|
| Orientation | 1 | 1992 | 1 | 0.090 |
Why?
|
| Pattern Recognition, Visual | 1 | 1992 | 2 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2011 | 17 | 0.090 |
Why?
|
| Homosexuality, Male | 3 | 2017 | 4 | 0.090 |
Why?
|
| Caudate Nucleus | 1 | 2011 | 1 | 0.090 |
Why?
|
| Putamen | 1 | 2011 | 1 | 0.090 |
Why?
|
| Bethanechol Compounds | 2 | 1988 | 2 | 0.080 |
Why?
|
| Antisocial Personality Disorder | 1 | 2010 | 3 | 0.080 |
Why?
|
| Impulsive Behavior | 1 | 2010 | 5 | 0.080 |
Why?
|
| Psychomotor Disorders | 1 | 2010 | 1 | 0.080 |
Why?
|
| Educational Status | 3 | 2015 | 41 | 0.080 |
Why?
|
| Stroop Test | 1 | 2010 | 1 | 0.080 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 2 | 0.080 |
Why?
|
| Intelligence Tests | 1 | 2010 | 6 | 0.080 |
Why?
|
| Genotype | 3 | 2014 | 85 | 0.080 |
Why?
|
| Personality | 1 | 2010 | 8 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 11 | 0.080 |
Why?
|
| Games, Experimental | 1 | 2009 | 1 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 19 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2011 | 13 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 17 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 5 | 1996 | 9 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 1999 | 17 | 0.070 |
Why?
|
| Frontal Lobe | 2 | 1995 | 7 | 0.070 |
Why?
|
| Schizophrenia | 2 | 2002 | 10 | 0.070 |
Why?
|
| Social Values | 1 | 2008 | 2 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2008 | 9 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 19 | 0.070 |
Why?
|
| Leadership | 1 | 2008 | 21 | 0.070 |
Why?
|
| HIV | 2 | 2011 | 3 | 0.070 |
Why?
|
| Infusion Pumps | 1 | 1988 | 1 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 147 | 0.070 |
Why?
|
| Time Factors | 3 | 2013 | 208 | 0.070 |
Why?
|
| Bisexuality | 2 | 2017 | 4 | 0.060 |
Why?
|
| Depressive Disorder, Major | 2 | 2003 | 13 | 0.060 |
Why?
|
| Viral Load | 2 | 2017 | 14 | 0.060 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 1995 | 4 | 0.050 |
Why?
|
| Homosexuality | 2 | 2015 | 2 | 0.050 |
Why?
|
| Gene Expression | 2 | 2014 | 45 | 0.050 |
Why?
|
| Alleles | 2 | 2014 | 65 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 1995 | 32 | 0.050 |
Why?
|
| Alcoholism | 2 | 2014 | 7 | 0.050 |
Why?
|
| Electroconvulsive Therapy | 1 | 2003 | 3 | 0.050 |
Why?
|
| Electric Stimulation | 1 | 2003 | 25 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 13 | 0.050 |
Why?
|
| Schizotypal Personality Disorder | 1 | 1982 | 1 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 7 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2002 | 5 | 0.050 |
Why?
|
| Communication | 1 | 1982 | 13 | 0.050 |
Why?
|
| Rehabilitation, Vocational | 1 | 2002 | 1 | 0.050 |
Why?
|
| Delusions | 1 | 2002 | 3 | 0.050 |
Why?
|
| Hallucinations | 1 | 2002 | 7 | 0.050 |
Why?
|
| Atrophy | 2 | 2011 | 10 | 0.040 |
Why?
|
| Gray Matter | 1 | 2020 | 2 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2014 | 27 | 0.040 |
Why?
|
| Zalcitabine | 1 | 1999 | 1 | 0.040 |
Why?
|
| Didanosine | 1 | 1999 | 1 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 1999 | 1 | 0.040 |
Why?
|
| Choice Behavior | 1 | 1999 | 5 | 0.040 |
Why?
|
| Pilot Projects | 1 | 1999 | 47 | 0.040 |
Why?
|
| Radiography | 2 | 2011 | 53 | 0.040 |
Why?
|
| Alkynes | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 1 | 0.040 |
Why?
|
| Movement | 1 | 2019 | 16 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2019 | 5 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2019 | 64 | 0.040 |
Why?
|
| Posture | 1 | 1998 | 8 | 0.040 |
Why?
|
| Cities | 1 | 2018 | 1 | 0.040 |
Why?
|
| Problem Solving | 1 | 1998 | 2 | 0.030 |
Why?
|
| Parietal Lobe | 2 | 1995 | 6 | 0.030 |
Why?
|
| Dominance, Cerebral | 2 | 1995 | 3 | 0.030 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2017 | 5 | 0.030 |
Why?
|
| Dopamine | 2 | 2014 | 14 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 10 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2017 | 4 | 0.030 |
Why?
|
| Tobacco Smoking | 1 | 2017 | 1 | 0.030 |
Why?
|
| Systems Biology | 1 | 2017 | 1 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 3 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 119 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 1050 | 0.030 |
Why?
|
| Language | 1 | 1996 | 12 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 2 | 1995 | 2 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2015 | 6 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1995 | 1 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 8 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 1995 | 83 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 1 | 0.030 |
Why?
|
| Language Disorders | 1 | 1995 | 2 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 1995 | 4 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2015 | 27 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2015 | 12 | 0.030 |
Why?
|
| Hematoma | 1 | 1995 | 3 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 25 | 0.030 |
Why?
|
| Methylphenidate | 1 | 1995 | 2 | 0.030 |
Why?
|
| Serotyping | 1 | 2014 | 1 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 1995 | 18 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 7 | 0.030 |
Why?
|
| Motivation | 1 | 1995 | 20 | 0.030 |
Why?
|
| Anomia | 1 | 1994 | 1 | 0.030 |
Why?
|
| Aphasia, Broca | 1 | 1994 | 1 | 0.030 |
Why?
|
| Smoking Prevention | 2 | 1986 | 6 | 0.030 |
Why?
|
| Biomarkers | 1 | 2015 | 101 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Marijuana Abuse | 1 | 2014 | 2 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Models, Neurological | 1 | 1994 | 4 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 1994 | 7 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 142 | 0.030 |
Why?
|
| Heroin | 1 | 2013 | 1 | 0.020 |
Why?
|
| Crack Cocaine | 1 | 2013 | 1 | 0.020 |
Why?
|
| Avoidance Learning | 2 | 2010 | 3 | 0.020 |
Why?
|
| Color Perception | 1 | 1992 | 1 | 0.020 |
Why?
|
| Activities of Daily Living | 2 | 1995 | 28 | 0.020 |
Why?
|
| Platelet Count | 1 | 2011 | 3 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2011 | 7 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 39 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 51 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 24 | 0.020 |
Why?
|
| Parkinson Disease | 1 | 1992 | 65 | 0.020 |
Why?
|
| Bethanechol | 2 | 1988 | 2 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 7 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 15 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 52 | 0.020 |
Why?
|
| Reference Values | 3 | 1998 | 28 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 33 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2010 | 1 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2010 | 12 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 7 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 44 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2011 | 106 | 0.020 |
Why?
|
| Verbal Behavior | 2 | 1994 | 3 | 0.020 |
Why?
|
| Anisotropy | 1 | 2008 | 11 | 0.020 |
Why?
|
| Behavior | 1 | 1988 | 5 | 0.020 |
Why?
|
| Affect | 1 | 2008 | 8 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 1988 | 29 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 9 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1988 | 85 | 0.020 |
Why?
|
| Biopsy | 1 | 1987 | 16 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 1986 | 2 | 0.010 |
Why?
|
| Counseling | 1 | 1986 | 3 | 0.010 |
Why?
|
| Regional Blood Flow | 2 | 1995 | 2 | 0.010 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2003 | 2 | 0.010 |
Why?
|
| Aversive Therapy | 1 | 1983 | 1 | 0.010 |
Why?
|
| Hypophysectomy | 1 | 1983 | 2 | 0.010 |
Why?
|
| Schizophrenic Language | 1 | 1982 | 1 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1982 | 4 | 0.010 |
Why?
|
| Morphine | 1 | 1983 | 12 | 0.010 |
Why?
|
| Motor Activity | 1 | 2003 | 53 | 0.010 |
Why?
|
| Chicago | 1 | 2002 | 160 | 0.010 |
Why?
|
| Reflex | 1 | 1998 | 1 | 0.010 |
Why?
|
| Electromyography | 1 | 1998 | 3 | 0.010 |
Why?
|
| Leg | 1 | 1998 | 2 | 0.010 |
Why?
|
| Rotation | 1 | 1998 | 10 | 0.010 |
Why?
|
| Forecasting | 1 | 1998 | 14 | 0.010 |
Why?
|
| Epilepsy | 1 | 1996 | 9 | 0.010 |
Why?
|
| Amobarbital | 1 | 1995 | 1 | 0.010 |
Why?
|
| Arteriovenous Malformations | 1 | 1995 | 1 | 0.010 |
Why?
|
| Bolivia | 1 | 1995 | 1 | 0.010 |
Why?
|
| Epilepsy, Generalized | 1 | 1995 | 2 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1995 | 7 | 0.010 |
Why?
|
| Social Behavior | 1 | 1995 | 8 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1994 | 28 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 1995 | 186 | 0.010 |
Why?
|
| Dopamine D2 Receptor Antagonists | 1 | 1994 | 1 | 0.010 |
Why?
|
| Neural Pathways | 1 | 1994 | 5 | 0.010 |
Why?
|
| Receptors, Dopamine D2 | 1 | 1994 | 5 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 1988 | 4 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 27 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1988 | 46 | 0.000 |
Why?
|
| Drug Tolerance | 1 | 1983 | 1 | 0.000 |
Why?
|
| Conditioning, Classical | 1 | 1983 | 2 | 0.000 |
Why?
|
| Rats | 1 | 1983 | 234 | 0.000 |
Why?
|